Read + Share
. van der Straten L, Stege CAM, Kersting S, et al. Fixed-duration venetoclax plus
obinutuzumab improves quality of life and geriatric impairments in FCR-unfit
patients with CLL. Blood. 2023;142(13):1131-1142. Blood 2024;144:341.
PMID: 39023875
|
 |
|
